Novo held its investor's day today. [https://www.novonordisk.com/investors/capital-markets-day-2026.html](https://www.novonordisk.com/investors/capital-markets-day-2026.html)
At its Capital Markets Day in September 2026, the drugmaker Novo outlined its strategic vision through 2030, highlighting plans to launch over five major blockbuster drugs, expand treatments into new medical areas, and 10x the manufacturing capacity of its oral weight-loss medicines. However, the company disappointed Wall Street and caused its stock to slide by declining to give a specific numerical percentage for its future revenue growth. Instead, management only stated that its revenue growth through 2030 would be in line with an industry average of 14 major pharmaceutical peers, signaling a notable slowdown from its massive historical growth rates as it prepares for rising competition and upcoming patent expirations.
It looks like if the company can keep some what below its recent trajectory it looks highly undervalued.
[https://userupload.gurufocus.com/2102047735212580864.png](https://userupload.gurufocus.com/2102047735212580864.png)